Summary of Risk Factors An investment in our securities involves various risks and you are urged to carefully consider the risks discussed under Item 1A “Risk Factors,” in this Annual Report on Form 10-K prior to making an investment in our securities. If any of the risks below or in Item 1A “Risk Factors” occurs, our business could be materially and adversely affected. As more fully described in Item 1A “Risk Factors,” the principal risks and uncertainties that may affect our business, financial condition and results of operations include, but are not limited to, the following: •We have incurred significant losses since our inception, and we may continue to incur losses, which could adversely affect the market price of our common stock and our ability to raise additional capital.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 297M | 297M | 266M | 202M | 149M | 100M |
| Net Income | -52M | -52M | -50M | -62M | -74M | -47M |
| EPS | $-0.80 | $-0.80 | $-0.81 | $-1.08 | $-1.33 | $-0.94 |
| Free Cash Flow | -46M | -46M | -19M | -34M | -87M | -34M |
| ROIC | -37.3% | -42.0% | -39.7% | -61.9% | -82.3% | -30.6% |
| Gross Margin | 66.3% | 66.3% | 68.5% | 68.1% | 62.4% | 56.3% |
| Debt/Equity | 0.00 | -6.32 | 22.00 | -5.82 | 3.89 | 0.87 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -33M | -33M | -34M | -49M | -65M | -44M |
| Operating Margin | -11.0% | -11.0% | -12.9% | -24.4% | -44.0% | -44.6% |
| ROE | 0.0% | - | -913.1% | - | -402.2% | -57.2% |
| Shares Outstanding | 65M | 65M | 62M | 57M | 56M | 50M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0 | N/A | N/A | 100M | 149M | 202M | 266M | 297M | 297M |
| Gross Margin | N/A | N/A | N/A | 56.3% | 62.4% | 68.1% | 68.5% | 66.3% | 66.3% |
| R&D | 6.5M | 4.0M | 1.7M | 2.1M | 4.7M | 6.6M | 9.2M | 9.6M | 9.6M |
| SG&A | 29M | 114M | 98M | 112M | 142M | 165M | 198M | 221M | 221M |
| EBIT | -46M | -99M | -153M | -44M | -65M | -49M | -34M | -33M | -33M |
| Op. Margin | N/A | N/A | N/A | -44.6% | -44.0% | -24.4% | -12.9% | -11.0% | -11.0% |
| Net Income | -47M | -90M | -163M | -47M | -74M | -62M | -50M | -52M | -52M |
| Net Margin | N/A | N/A | N/A | -47.0% | -50.1% | -30.5% | -18.9% | -17.4% | -17.4% |
| Non-Recurring | 0 | 0 | 3.0M | 0 | 0 | 0 | 0 | 1.4M | 1.4M |
| Returns on Capital | |||||||||
| ROIC | -55.5% | -58.9% | -73.2% | -30.6% | -82.3% | -61.9% | -39.7% | -42.0% | -37.3% |
| ROE | -55.5% | -113.3% | N/A | -57.2% | -402.2% | N/A | -913.1% | N/A | 0.0% |
| ROA | -27.3% | -37.4% | -78.0% | -18.2% | -41.8% | -32.6% | -21.7% | -22.5% | -22.9% |
| Cash Flow | |||||||||
| Op. Cash Flow | -26M | -93M | -58M | -33M | -85M | -34M | -18M | -42M | -42M |
| Free Cash Flow | -26M | -94M | -59M | -34M | -87M | -34M | -19M | -46M | -46M |
| Owner Earnings | -33M | -107M | -75M | -49M | -99M | -56M | -46M | -70M | -70M |
| CapEx | 9K | 345K | 815K | 393K | 1.6M | 473K | 1.5M | 3.4M | 3.4M |
| Maint. CapEx | 9K | 4.1M | 7.0M | 5.6M | 3.7M | 5.1M | 5.3M | 7.5M | 7.5M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 9K | 4.1M | 7.0M | 5.6M | 3.7M | 5.1M | 5.3M | 7.5M | 7.5M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 7.0M | 9.5M | 11M | 9.6M | 11M | 16M | 22M | 21M | 21M |
| Debt Repayment | 0 | 1.0M | 523K | 76M | 500K | 46K | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | -76M | -56M | -14M | -221M | -36M | -5.3M | -52M | 38M | 92M |
| Cash & Equiv. | 93M | 110M | 103M | 146M | 54M | 63M | 87M | 54M | 54M |
| Long-Term Debt | 0 | 74M | 0 | 71M | 72M | 120M | 122M | 146M | 146M |
| Debt/Equity | 0.20 | 0.93 | -1.28 | 0.87 | 3.89 | -5.82 | 22.00 | -6.32 | 0.00 |
| Interest Coverage | N/A | -19.2 | N/A | -31.8 | -7.2 | -3.6 | -1.8 | -1.7 | -1.7 |
| Equity | 84M | 79M | -73M | 82M | 18M | -21M | 5.5M | -23M | -23M |
| Total Assets | 172M | 240M | 209M | 257M | 178M | 189M | 233M | 226M | 226M |
| Total Liabilities | 87M | 161M | 282M | 176M | 159M | 210M | 227M | 249M | 249M |
| Intangibles | 77M | 81M | 77M | 72M | 70M | 68M | 70M | 69M | 69M |
| Retained Earnings | -123M | -213M | -376M | -423M | -497M | -559M | -609M | -661M | -661M |
| Working Capital | 89M | 128M | -53M | 121M | 54M | 64M | 88M | 68M | 68M |
| Current Assets | 94M | 152M | 128M | 179M | 101M | 112M | 151M | 143M | 143M |
| Current Liabilities | 5.3M | 24M | 180M | 58M | 47M | 48M | 63M | 75M | 75M |
| Per Share Data | |||||||||
| EPS | -1.92 | -3.19 | -4.83 | -0.94 | -1.33 | -1.08 | -0.81 | -0.80 | -0.80 |
| Owner EPS | -1.34 | -3.79 | -2.24 | -0.98 | -1.78 | -0.97 | -0.73 | -1.09 | -1.09 |
| Book Value | 3.46 | 2.82 | -2.16 | 1.64 | 0.33 | -0.36 | 0.09 | -0.36 | -0.36 |
| Cash Flow/Share | -1.05 | -3.31 | -1.71 | -0.67 | -1.52 | -0.60 | -0.29 | -0.65 | -0.68 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 24.4M | 28.2M | 33.8M | 49.8M | 55.9M | 57.1M | 62.2M | 64.6M | 64.6M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -5.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.4 | 4.2 | N/A | 4.1 | 20.7 | N/A | 125.0 | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | 4.6 | 3.6 | 2.5 | 3.1 | 2.1 | 1.0 |
| FCF Yield | -8.8% | -27.9% | -51.0% | -10.2% | -22.5% | -5.8% | -2.8% | -10.3% | -15.9% |
| Market Cap | 290M | 336M | 115M | 332M | 384M | 590M | 690M | 445M | 287M |
| Avg. Price | 16.88 | 17.93 | 5.17 | 9.29 | 9.63 | 8.87 | 13.35 | 9.45 | 4.44 |
| Year-End Price | 11.90 | 11.89 | 3.41 | 6.66 | 6.86 | 10.33 | 11.09 | 6.90 | 4.44 |
Evolus, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 64.3%.
Evolus, Inc. (EOLS) has a 5-year average return on invested capital (ROIC) of -51.3%. This is below average and may indicate limited pricing power.
Evolus, Inc. (EOLS) has a market capitalization of $287M. It is classified as a small-cap stock.
Evolus, Inc. (EOLS) does not currently pay a regular dividend.
Evolus, Inc. (EOLS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Evolus, Inc. (EOLS) reported annual revenue of $297 million in its most recent fiscal year, based on SEC EDGAR filings.
Evolus, Inc. (EOLS) has a net profit margin of -17.4%. The company is currently unprofitable.
Evolus, Inc. (EOLS) generated $-46 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Evolus, Inc. (EOLS) reported earnings per share (EPS) of $-0.80 in its most recent fiscal year.
Evolus, Inc. (EOLS) has a 5-year average gross margin of 64.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 8 years of financial data for Evolus, Inc. (EOLS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Evolus, Inc. (EOLS) has a book value per share of $-0.36, based on its most recent annual SEC filing.